Literature DB >> 6974218

Polyclonal activation of human B lymphocytes by Fc fragments. I. Characterization of the cellular requirements for Fc fragment-mediated polyclonal antibody secretion by human peripheral blood B lymphocytes.

E L Morgan, W O Weigle.   

Abstract

Fc fragments derived from human immunoglobulin were found to be capable of inducing both a proliferative and polyclonal antibody response in human peripheral blood lymphocyte cultures. The cell population proliferating in response to Fc fragments belongs to the B cell lineage. Expression of polyclonal antibody formation requires the presence of both adherent monocytes and T cells. The role of the monocyte is to enzymatically cleave the Fc fragment into 19,000 mol wt Fc subfragments that are then able to induce polyclonal antibody secretion. Stimulation of polyclonal antibody production by Fc subfragments occurs in the absence of adherent monocytes but still requires the presence of T cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974218      PMCID: PMC2186451          DOI: 10.1084/jem.154.3.778

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  Activation of human B lymphocytes XVI. Cellular requirements, interactions, and immunoregulation of pokeweed mitogen-induced total-immunoglobulin producing plaque-forming cells in peripheral blood.

Authors:  A S Fauci; G Whalen; C Burch
Journal:  Cell Immunol       Date:  1980-08-15       Impact factor: 4.868

2.  T cell regulation of polyclonal B cell responsiveness. I. Helper effects of T cells.

Authors:  M G Goodman; W O Weigle
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

3.  Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells.

Authors:  S A Rosenberg; P E Lipsky
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

4.  Polyclonal activation of murine B lymphocytes by Fe fragments. II. Replacement of T cells by a soluble helper T cell-replacing factor (TRF).

Authors:  M L Thoman; E L Morgan; W O Weigle
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

5.  Polyclonal activation of murine B lymphocytes by Fc fragments. I. The requirement for two signals in the generation of the polyclonal antibody response induced by Fc fragments.

Authors:  E L Morgan; W O Weigle
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

6.  Aggregated human gamma-globulin-induced proliferation and polyclonal activation of murine B lymphocytes.

Authors:  E L Morgan; W O Weigle
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

7.  Polyclonal activation of human lymphocytes in vitro-II. Reappraisal of T and B cell-specific mitogens.

Authors:  H M Dosch; R K Schuurman; E W Gelfand
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

8.  Regulation of the immune response. I. The potentiation of in vivo and in vitro immune responses by Fc fragments.

Authors:  E L Morgan; S M Walker; M L Thoman; W O Weigle
Journal:  J Exp Med       Date:  1980-07-01       Impact factor: 14.307

9.  The requirement for adherent cells in the Fc fragment-induced proliferative response of murine spleen cells.

Authors:  E L Morgan; W O Weigle
Journal:  J Exp Med       Date:  1979-08-01       Impact factor: 14.307

10.  Regulation of Fc fragment-induced murine spleen cell proliferation.

Authors:  E L Morgan; W O Weigle
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Feedback regulation of antibody production: a role in rheumatoid arthritis?

Authors:  J K Kalsi; N D Hall
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

2.  IgE Fc receptor positive T and B lymphocytes in patients with the hyper IgE syndrome.

Authors:  L F Thompson; H L Spiegelberg; R H Buckley
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

3.  Isolation and identification of a biologically active peptide derived from the CH3 domain of human IgG1.

Authors:  E L Morgan; T E Hugli; W O Weigle
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

Review 4.  Regulation of immune response by components of the complement cascade and their activated fragments.

Authors:  W O Weigle; M G Goodman; E L Morgan; T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1983

5.  Lymphocyte phenotype and function in pseudolymphoma associated with Sjögren's syndrome.

Authors:  R I Fox; T C Adamson; S Fong; C A Robinson; E L Morgan; J A Robb; F V Howell
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

6.  Potentiation of specific human in vitro immune responses by the Fc portion of human immunoglobulin.

Authors:  E L Morgan; W O Weigle
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

Review 7.  Fc receptor--more answers, more questions.

Authors:  L Fornůsek; V Vĕtvicka
Journal:  Folia Microbiol (Praha)       Date:  1984       Impact factor: 2.099

8.  Signal peptides and trans-membrane regions are broadly immunogenic and have high CD8+ T cell epitope densities: Implications for vaccine development.

Authors:  Riva Kovjazin; Ilan Volovitz; Yair Daon; Tal Vider-Shalit; Roy Azran; Lea Tsaban; Lior Carmon; Yoram Louzoun
Journal:  Mol Immunol       Date:  2011-02-12       Impact factor: 4.407

9.  Characterization of novel multiantigenic vaccine candidates with pan-HLA coverage against Mycobacterium tuberculosis.

Authors:  Riva Kovjazin; David Shitrit; Rachel Preiss; Ilanit Haim; Lev Triezer; Leonardo Fuks; Abdel Rahman Nader; Meir Raz; Ritta Bardenstein; Galit Horn; Nechama I Smorodinsky; Lior Carmon
Journal:  Clin Vaccine Immunol       Date:  2013-01-02

10.  Polyneuropathy associated with IgA monoclonal gammopathy: a hypothesis of its pathogenesis.

Authors:  R Nemni; A Mamoli; R Fazio; M Camerlingo; A Quattrini; I Lorenzetti; M Comola; G Galardi; N Canal
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.